Baillie Gifford: the weight-loss drug with huge growth potential

Baillie Gifford investment manager Ross Mathison discusses Novo Nordisk’s weight-loss drug Wegovy and other related treatments and the growth opportunity they offer. Capital at risk.

Recorded - February 2024.

Back to all videos

Sign up for monthly updates

Stay informed about investment companies with our regular emails.

First name

Surname

Email address

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Baillie Gifford: the weight-loss drug with huge growth potential

Sign up for monthly updates

You are now leaving our website